Pfizer preps for Zoetis animal health spin-out but full sale still on the cards?
This article was originally published in Scrip
Pfizer filed paperwork for a $100 million initial public offering on behalf of Zoetis on 13 August with plans to transfer the pharmaceutical giant's animal health business to the new company after the IPO is completed during the first half of 2013.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.